Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination antibiotic regimen consisting of three distinct antimicrobial agents: 1. **Cefuroxime**: A second-generation cephalosporin with broad-spectrum activity against gram-positive and gram-negative bacteria. It is resistant to beta-lactamase enzymes. 2. **Gentamicin**: An aminoglycoside antibiotic effective against many gram-negative bacteria. It works by binding to bacterial ribosomes and inhibiting protein synthesis. 3. **Metronidazole**: An antibiotic and antiprotozoal medication particularly effective against anaerobic bacteria and certain parasites. This combination provides comprehensive antimicrobial coverage: - Cefuroxime covers many gram-positive and gram-negative organisms - Gentamicin enhances coverage against gram-negative bacteria - Metronidazole provides coverage against anaerobic bacteria The combination is used primarily for treating serious bacterial infections, particularly intra-abdominal infections, surgical prophylaxis, and certain gynecological infections[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cefuroxime + Gentamicin + Metronidazole.